Introduction
The renin -angiotensin system is im portant in the regulation of blood pressure and angiotensinconverting enzyme (ACE; peptidyldipeptide hy drolase, EC 3.4.15.1). Inhibitors have been of great value for their hypotensive effect through this sys tem. Competitive inhibitors of ACE were first ob tained from venom of snakes such as Bothrops jararaca (Cheung et al.,1980) and Agkistrodon halys blomhoffi (Kato and Suzuki, 1971) . These inhibi tors have many proline residues. A nother inhibitor of ACE has been isolated from an acid extract of tuna (Neothunnus macropterus) muscle (Kohama et al., 1989) . This peptide was found to be a non competitive inhibitor different from many natural peptide inhibitors (Kohama et al., 1994) . The amino acid sequence of tuna ACE inhibitor was similar as though not identical, to segments within the vertebrate GAPDH family (Kohama et al., 1989) .
Thus the attention of many laboratories were focused on a family of ACE inhibitory peptides excised from vertebrate and prokaryote G A PD H (glyceraldehyde-3-phosphate dehydrogenase, EC 1.2.1.12) by acid-limited proteolysis (Kohama et al., 1989) .
In this paper, the inhibitory effect of a synthetic peptide, identical to the peptide 79-86 of the hu man muscle GAPDH was studied. The complete amino acid sequence of this enzyme was estabKj value of 1.6 [xm. The inhibitor of ACE sequence of the new inhibitor was comlished earlier in our laboratory (Nowak et al., 1989) . The structure of the human peptide is sim ilar to the active inhibitors of ACE from rat, chicken and tuna muscle glyceraldehyde-3-phosphate dehydrogenase.
Materials and Methods
Materials -Peptidyldipeptide hydrolase (ACE; EC 3.4.15.1) from rabbit lung, hippuryl-L-histydyl-L-leucine (Hip-His-Leu), L-histydyl-L-leucine (His-Leu) were purchased from Sigma Chemical (Mo., USA).
All others reagents and solvents were obtained from Serva, Germany.
Peptide synthesis -The peptide: Pro-Glu-AsnIle-Lys-Trp-Gly-Asp was synthesized by conven tional solid phase m ethod using an autom ated peptide synthesizer (Applied Biosystems Inc., model -430 A), followed by treatm ent with hy drogen fluoride to cut off the support resins and to remove all of the protecting groups (Merrifield, 1985) . The synthesized peptide was purfied by re verse phase high performance liquid chromatogra phy on Develosil ODS-7 column (0.46 x 25 cm) eluted with a 5 -3 0 % acetonitrile in 0.05% HC1 (linear gradient). A fter that the peptide was run on a Asahipak GS-220 column (0.76 x 25 cm) eluted with 50 mM sodium phosphate buffer, pH 7.0. The results of amino acid analyses and se quence analyses agreed well with expected values.
0939-5075/2000/0700-0657 $ 06.00 © 2000 Verlag der Zeitschrift für Naturforschung, Tübingen • www.znaturforsch.com ■ D ACE activity assay -The activity of ACE was assayed by fluorometrically (Cheung et al., 1973) of the rate of formation of histidylleucine from Hip-His-Leu. Incubations were carried out at 37 °C in final volume of 0.25 ml, which contained 100 mM potassium phosphate buffer (pH 8.3), 300 mM NaCl, enzyme (activity 3.4 U/mg) and 2.5 m M Hip-His-Leu. The enzymatic reactions were term inated by addition of 1.45 ml of 0.3 m N aOH and 100 (xl 0.2% o-phthaldialdehyde was then added, followed after 10 min. by 0.2 ml of 3 m HC1. The fluorescence was measured with PerkinElm er MPF 3L spectrofluorimeter (Xex=360 nm, X.f]=500 nm).
ACE activity was assayed in the presence or absence of inhibitor and compared to controls containing no inhibitor. In other experiments our inhibitor was preincubated with various concen trations of ZnCl2 for 5 min. at 37 °C before the reaction was started.
Results
The amino acid sequence of the peptide inhibi tor of ACE, obtained synthetically, was as follows: Pro-Glu-Asn-Ile-Lys-Trp-Gly-Asp. This sequence corresponds to the peptide 79-86 from human skeleton muscle GAPDH. Figure 1 shows the Lineweaver-Burk plot of in hibition of rabbit lung ACE catalyzed hydrolysis of Hip-His-Leu by synthetic peptide. Activity of ACE in control sample (non-inhibited) was 3.4 [imol • mg protein-1 • m in-1. This peptide inhibited the enzyme non-competitively. The Kj value was calculated by Dixon method was 1.6 |i m . I50 value (concentration of inhibitor producing a 50% inhi bition of ACE) was 3.7 (.i m . With great excess of this inhibitor only about 80% inhibition of ACE was obtained.
It is well known, that EDTA inhibits the activity of ACE by chelating the enzyme bound Z n+2. This inhibition may be reversed by addition of Z n+2 -containing solutions to the reaction mixture. R e sults are shown in Table I . The addition of Z n+2 -ions reversed completely the inhibition by EDTA, but had only minor influence on the inhibition by the synthetic peptide, diminishing it by 5 and 10%.
When this synthetic peptide (inhibitor) was pre incubated without ZnCl2, its ACE inhibitory activ ity was about 50%. When 10 or 20 (.i m ZnC l2 was Fig. 1 . Lineweaver-Burk plots of inhibition of rabbit lung ACE by synthetic peptide corresponding to sequence of GA PD H . ACE concentrations was 6 mU for assay, 1 unit of ACE activity is defined as the amount catalyzing the formation of 1 (imol of hippuric acid from Hip-HisLeu in 1 min. at 37 °C. Inhibitor concentration: • -0 (AM, ▲ -3 (AM, ■ -6 (AM. added respective inhibitory activities were 4 5 -41%. The influence of EDTA on ACE -which was added after preincubation with ZnCl2 is shown in Table I . These data indicate that this syn thetic peptide that corresponds to sequence 7 9 -86 from human skeleton muscle GAPDH does in teract with Z n+2 -ions (Krotkiewska and Banas, 1992) .
Discussion
Angiotensin -converting enzyme catalyses the cleavage of the C-terminal dipeptide L-His-L-Leu of the decapeptide angiotensin I, generating the biologically highly active vasopressor angiotensin II.
Since ACE is a dipeptidyl carboxypeptidase, the C-terminal tripeptide fragment of the inhibitory peptides from snake venom is predominant in its competitive binding to the enzyme. The terminal aromatic amino acid is favorable for effective binding of peptide inhibitors to the active site of the enzyme (Kohama et al., 1991) . The synthetic peptide shows a non-competitive mode of inhibi tion. All of the octapeptides in Table II have a dicarboxylic acid Asp as terminal and Gly as pe nultimate, and the amino acid sequence is different from those of the venom peptide family (Cheung and Cushman, 1973; Cheung et al., 1980) . These facts may support a non-competitive inhibi tion of ACE by these inhibitors. Differences of amino acid sequence evident at the position 80 of G A PD H -derived peptides seem not to influence their inhibitory activity.
ACE contains zinc ions which plays an im por tant role in the active site (Wei et al., 1991) . EDTA shows a powerful inhibitory activity by chelating 659 the ACE active site for zinc. Its main inhibitory mechanism was shown to be a chelating effect, be cause saturation with exogenous zinc abolishes in hibition by EDTA. However, our synthetic pep tide did not show any zinc chelating effect. It seems that its inhibitory mechanism is non-competitive in our assay condition with Hip-His-Leu. Although our peptide is only a moderately strong inhibitor of ACE, compared to known ACE inhibitors, it is noteworthy that this peptide from human muscle G A PD H inhibits rabbit lung ACE in a non-competitive manner. In pathological states resulting in protein degradation G A PD H could be proteolized. It could be the reason of ad ditional decrease of blood pressure.
